Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?

Mouliou, Dimitra S.; Dardiotis, Efthimios

doi:10.1016/j.msard.2022.103938

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was evident from the pre-pandemic years that currently we have therapies and drugs but with no specific ‘disease’ label, as several therapeutic strategies and drugs can target and be applied to more than one disease; the pandemic also proved that fact. For example, a mono-clonal antibody studied in multiple sclerosis (MS) has been studied in COVID-19 as well [ 67 ]. Doubtlessly, current lifestyle affects genetics to a large extent, and as climate change is progressing, new emerging infectious diseases will arise or past infectious pathogens will appear again [ 2 ].…”

Section: From Current To Future Coming Public Health and The Molecula...mentioning

confidence: 99%

The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic

Mouliou¹

2023

Diseases

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic took place during the years 2020–2022 and the virus, named SARS-CoV-2, seems likely to have resulted in an endemic disease. Nevertheless, widespread COVID-19 has given rise to several major molecular diagnostics’ facts and concerns that have emerged during the overall management of this disease and the subsequent pandemic. These concerns and lessons are undeniably critical for the prevention and control of future infectious agents. Furthermore, most populaces were introduced to several new public health maintenance strategies, and again, some critical events arose. The purpose of this perspective is to thoroughly analyze all these issues and the concerns, such as the molecular diagnostics’ terminologies, their role, as well as the quantity and quality issues with a molecular diagnostics’ test result. Furthermore, it is speculated that society will be more vulnerable in the future and prone to emerging infectious diseases; thus, a novel preventive medicine’s plan for the prevention and control of future (re)emerging infectious diseases is presented, so as to aid the early prevention of future epidemics and pandemics.

show abstract

Section: From Current To Future Coming Public Health and The Molecula...mentioning

confidence: 99%

The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic

Mouliou¹

2023

Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another old study reported higher values for bacterial meningitis (>100 mg/L), and recent data have also supported such evidence to a great extent, yet cutoff values among studies are divergent [ 1000 , 1001 , 1002 , 1003 ]. Furthermore, studies on John Cunningham virus (JCv) seem limited, but the current literature suggests that it may reactivate after immunosuppression, leading to higher ultrasensitive CRP results [ 1004 , 1005 ]. In addition, a study concluded that notably elevated CRP can indicate mortality in tetanus, yet a case report revealed relatively normal values; however, data are sparse.…”

Section: Current Evidence On C-reactive Protein and Potential Conditionsmentioning

confidence: 99%

“…In addition, a study concluded that notably elevated CRP can indicate mortality in tetanus, yet a case report revealed relatively normal values; however, data are sparse. CRP can be notably elevated in cysticercosis (>500 mg/L), but again, there exist few data on this condition [ 1004 , 1005 , 1006 ].…”

Section: Current Evidence On C-reactive Protein and Potential Conditionsmentioning

confidence: 99%

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians

Mouliou

2023

Diseases

Self Cite

View full text Add to dashboard Cite

The current literature provides a body of evidence on C-Reactive Protein (CRP) and its potential role in inflammation. However, most pieces of evidence are sparse and controversial. This critical state-of-the-art monography provides all the crucial data on the potential biochemical properties of the protein, along with further evidence on its potential pathobiology, both for its pentameric and monomeric forms, including information for its ligands as well as the possible function of autoantibodies against the protein. Furthermore, the current evidence on its potential utility as a biomarker of various diseases is presented, of all cardiovascular, respiratory, hepatobiliary, gastrointestinal, pancreatic, renal, gynecological, andrological, dental, oral, otorhinolaryngological, ophthalmological, dermatological, musculoskeletal, neurological, mental, splenic, thyroid conditions, as well as infections, autoimmune-supposed conditions and neoplasms, including other possible factors that have been linked with elevated concentrations of that protein. Moreover, data on molecular diagnostics on CRP are discussed, and possible etiologies of false test results are highlighted. Additionally, this review evaluates all current pieces of evidence on CRP and systemic inflammation, and highlights future goals. Finally, a novel diagnostic algorithm to carefully assess the CRP level for a precise diagnosis of a medical condition is illustrated.

show abstract

The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

Sacchi,

Pelazza,

Bertolotti

et al. 2023

Autoimmunity

View full text Add to dashboard Cite

Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?

Cited by 5 publications

References 10 publications

The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic

The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians

The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

Contact Info

Product

Resources

About